MX2021009679A - Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno. - Google Patents

Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno.

Info

Publication number
MX2021009679A
MX2021009679A MX2021009679A MX2021009679A MX2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A MX 2021009679 A MX2021009679 A MX 2021009679A
Authority
MX
Mexico
Prior art keywords
ibuprofen
coating
pharmaceutical compositions
aeration
preserving
Prior art date
Application number
MX2021009679A
Other languages
English (en)
Inventor
Rosaleen Mclaughlin
Simon Andrew Martyn Howes
Jonathon Whitehouse
Adam Parker
Craig Wheadon
Original Assignee
Catalent Uk Swindon Zydis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Uk Swindon Zydis Ltd filed Critical Catalent Uk Swindon Zydis Ltd
Publication of MX2021009679A publication Critical patent/MX2021009679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones y métodos farmacéuticos para preparar composiciones farmacéuticas que comprenden Ibuprofeno usando métodos de mezcla sin solvente. El exceso de material de revestimiento que no está unido al Ibuprofeno revestido puede ser retirado mediante un proceso de tamizado. Los índices de revestimiento y dosificación también pueden ser optimizados para minimizar la cantidad de exceso de material de revestimiento no unido. Adicionalmente, las composiciones pueden formularse para preservar el revestimiento funcional del Ibuprofeno revestido y para minimizar la aireación del Ibuprofeno cuando se mezcla en suspensión.
MX2021009679A 2019-02-22 2020-02-21 Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno. MX2021009679A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962809293P 2019-02-22 2019-02-22
US201962809287P 2019-02-22 2019-02-22
US201962809307P 2019-02-22 2019-02-22
PCT/GB2020/050420 WO2020169989A1 (en) 2019-02-22 2020-02-21 Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen

Publications (1)

Publication Number Publication Date
MX2021009679A true MX2021009679A (es) 2021-09-10

Family

ID=69740393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009679A MX2021009679A (es) 2019-02-22 2020-02-21 Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno.

Country Status (17)

Country Link
US (3) US11166919B2 (es)
EP (2) EP4282409A3 (es)
JP (1) JP2022521318A (es)
KR (1) KR20210129649A (es)
CN (1) CN113490486A (es)
AU (1) AU2020223894A1 (es)
BR (1) BR112021016421A2 (es)
CA (1) CA3129395A1 (es)
ES (1) ES2966816T3 (es)
GB (2) GB2585414B (es)
HU (1) HUE064472T2 (es)
IL (1) IL285653A (es)
MX (1) MX2021009679A (es)
PL (1) PL3927312T3 (es)
SG (1) SG11202108690YA (es)
TW (1) TW202045153A (es)
WO (1) WO2020169989A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109022UA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
MX2021009844A (es) * 2019-02-22 2021-09-10 Catalent Uk Swindon Zydis Ltd Conservacion de particulas de ingredientes farmaceuticos activos revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspension acuosa.
CA3129395A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
CN115968281A (zh) * 2020-07-31 2023-04-14 康特伦英国斯温顿捷迪斯有限公司 包含经包衣api的药物组合物
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB211423A (en) 1923-10-06 1924-02-21 Leopold Seeger Improved means for locking nuts
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
IT1183574B (it) 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
WO1992021328A1 (en) 1991-05-28 1992-12-10 Affinity Biotech, Inc. Chewable drug-delivery composition
DE4119116C2 (de) 1991-06-10 1997-08-07 Boehme Chem Fab Kg Biologisch leicht eliminierbare Entschäumer für wäßrige Systeme
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
GB9814534D0 (en) 1998-07-03 1998-09-02 Courtaulds Coatings Holdings Powder coating compositions
FR2785539B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
JP2002012557A (ja) 2000-06-28 2002-01-15 Lion Corp 内服薬組成物
ES2396598T3 (es) 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
IN192750B (es) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
CA2449731A1 (en) * 2001-06-07 2002-12-19 Tanabe Seiyaku Co., Ltd. Functional grain-containing preparations quickly disintegrated in the oral cavity
JP2003055197A (ja) 2001-06-07 2003-02-26 Tanabe Seiyaku Co Ltd 機能性粒子含有口腔内速崩壊性製剤
US20030185096A1 (en) 2002-11-26 2003-10-02 Hollstein Thomas E. Apparatus and methods for dispensing minute amounts of liquid
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US20040170686A1 (en) 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
EP1621186A1 (en) 2004-07-29 2006-02-01 Cephalon France Modafinil oral lyophilizate
US8802145B2 (en) * 2004-10-28 2014-08-12 Pantec Ag Highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step
WO2006048895A1 (en) 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
US20070148099A1 (en) 2005-12-27 2007-06-28 Burke Susan E Use of aroma compounds as defoaming agents for ophthalmic solutions with high concentrations of surfactants
EP1978939A2 (en) 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
US20070292508A1 (en) 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
CA2664097A1 (en) * 2006-09-20 2008-03-27 Monosol Rx, Llc Edible water-soluble film containing a foam reducing flavoring agent
AU2007308986A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
NZ587611A (en) 2008-02-28 2012-07-27 Rp Scherer Technologies Llc Process to minimize polymorphism
EP2391345B1 (en) 2009-01-28 2014-09-03 Novartis AG Galenic formulations comprising aliskiren
WO2011063531A1 (en) 2009-11-27 2011-06-03 Nuvo Research Inc. Topical ibuprofen formulations
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CN102579390A (zh) 2011-08-03 2012-07-18 天津市嵩锐医药科技有限公司 布洛芬定时释药三层片药物组合物及其制备方法
WO2013024373A1 (en) 2011-08-12 2013-02-21 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
RU2476206C1 (ru) * 2011-11-22 2013-02-27 Виктор Львович Лимонов Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
WO2013183062A2 (en) 2012-06-05 2013-12-12 Rubicon Research Private Limited Palatable formulations of ibuprofen
US9107851B2 (en) 2012-10-15 2015-08-18 New Jersey Institute Of Technology Solventless mixing process for coating pharmaceutical ingredients
AU2014228861B2 (en) 2013-03-15 2018-05-24 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of topiramate
WO2017080566A1 (en) * 2015-11-09 2017-05-18 Rontis Hellas S.A. Stable analgesic pharmaceutical composition and process for the preparation thereof
MX2021009844A (es) 2019-02-22 2021-09-10 Catalent Uk Swindon Zydis Ltd Conservacion de particulas de ingredientes farmaceuticos activos revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspension acuosa.
CA3129395A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
SG11202109022UA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
EP4268801A3 (en) 2019-02-22 2024-01-17 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing

Also Published As

Publication number Publication date
JP2022521318A (ja) 2022-04-06
BR112021016421A2 (pt) 2021-10-13
EP4282409A3 (en) 2024-02-28
GB2585414B (en) 2023-06-14
GB202107172D0 (en) 2021-06-30
GB2597577B (en) 2023-09-20
US11166919B2 (en) 2021-11-09
TW202045153A (zh) 2020-12-16
US11077067B2 (en) 2021-08-03
US20210353551A1 (en) 2021-11-18
AU2020223894A1 (en) 2021-10-14
GB2585414A (en) 2021-01-13
US20200268676A1 (en) 2020-08-27
SG11202108690YA (en) 2021-09-29
US20200390716A1 (en) 2020-12-17
EP3927312C0 (en) 2023-09-13
US11931464B2 (en) 2024-03-19
GB2597577A (en) 2022-02-02
EP3927312B1 (en) 2023-09-13
ES2966816T3 (es) 2024-04-24
HUE064472T2 (hu) 2024-03-28
KR20210129649A (ko) 2021-10-28
CN113490486A (zh) 2021-10-08
WO2020169989A1 (en) 2020-08-27
PL3927312T3 (pl) 2024-02-26
IL285653A (en) 2021-09-30
GB202002484D0 (en) 2020-04-08
EP3927312A1 (en) 2021-12-29
EP4282409A2 (en) 2023-11-29
CA3129395A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
MX2021009679A (es) Minimizacion de aglomeracion, aireacion y conservacion del revestimiento de composiciones farmaceuticas que comprenden ibuprofeno.
ZA202202966B (en) Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
NZ569012A (en) Powder compositions for inhalation comprising a force-controlling agent
MX342561B (es) Proceso para fabricar un alimento para mascotas en la forma de una croqueta recubierta.
NZ602338A (en) Fertilizer composition containing micronutrients and methods of making same
WO2009104187A3 (en) Bone graft material and uses thereof
JO3174B1 (ar) حمض الميورات المضغوط لاسمدة البوتاس التي تحتوي على مغذيات و طرق صناعتها
MX2021013774A (es) Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
EA201891952A1 (ru) Композиция удобрений с нанесенным распылением покрытием
MX361284B (es) Particulas de ingrediente activo, recubiertas de goma laca, con propiedades de liberacion controlada, a valores altos de ph, proceso para su fabricacion, y uso de las mismas.
AR118159A1 (es) Minimización de aglomeración, aireación y conservación del revestimiento de composiciones farmacéuticas que comprenden ibuprofeno
MX2020007320A (es) Proceso para preparar una composicion en polvo.
EP4268801A3 (en) Minimizing aeration of suspensions during in-line mixing
DE50202939D1 (de) Verfahren zur herstellung von inhalationspulvern
NZ611664A (en) Plant growth enhancing mixture and method of applying same
DE60138131D1 (de) Verfahren zur herstellung von methionin-haltigen granulaten
MX2023001004A (es) Composiciones farmaceuticas que comprenden un ingrediente farmaceutico activo (api) recubierto.
MY190651A (en) Highly porous powdered slaked lime composition
JPS6042288A (ja) 長期肥効を有する肥料
NZ739020A (en) Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof
JP2009523147A5 (es)
MX2021008538A (es) Sistemas y métodos para elaborar composiciones y productos termoplásticos.
CN104496300A (zh) 一种用于水体清洁的清洁球及其制备方法
CN104530835A (zh) 一种涂料
CN103739387A (zh) 一种以硅砂为芯的包膜控释肥及其制备方法